Our previous studies indicated that ERO1A genetic deletion in TNBC murine models impaired VEGF folding under hypoxic conditions, affecting cancer fitness in terms of angiogenesis and dissemination, and potentiated the otherwise scant effects of antiangiogenic therapy solely targeting VEGFA [16, 19, 23]. The gene discussed is VEGFA; the disease is cancer.